Contributions
Abstract: P863
Type: Poster
Abstract Category: Clinical aspects of MS - MS and gender
Background: Multiple Sclerosis (MS) often affects women at the peak of their reproductive capacity.
Several studies have shown successful reproductive outcomes in women with MS. However, there is a lack of prospective disease-specific, rather then medication-specific, real-world pregnancy registries. There is also a paucity of data related to developmental pediatric outcomes in children born to mothers with MS. Here, we propose a region-specific MS pregnancy study focused on longer-term maternal and pediatric outcomes.
Methods: We developed a data repository that will follow women with MS from any stage of conception to three years post-partum. This prospective cohort investigation will recruit 600 patients from 11 Multiple Sclerosis Clinics and Centers in the New England region of the United States. RedCap database will be used for data processing and storage. The principle site will collect neurologic, obstetric, and pediatric routine care information throughout pregnancy attempts, pregnancy trimesters and for 3 years post partum. Telephone interviews will be conducted every three months during pregnancy and at specified time points post partum. Decoded, de-identified information will be made available for subsequent aggregate analysis.
Results: This unique registry will assess real world practices and outcomes in pregnant MS patients and their children. We expect that maternal outcomes may be influenced by the overall duration off disease-modifying therapy (DMT), lactation choices post-partum, and disease severity pre-partum. We anticipate that pediatric outcomes may be influenced by level of maternal neurologic disability peri-partum, exposure to immune-modulating medications in early pregnancy and socio-economic stressors.
Conclusion: This is the first prospective regional MS pregnancy registry in the United States. Results from this study will contribute to our understanding of maternal and pediatric outcomes in MS and to the development of effective pregnancy and post-partum management programs in this patient population.
Disclosure: Tatenda D Mahlanza: nothing to disclose
Maria Houtchens: Unrestricted research grants from Biogen Idec, GenzymeConsulting honorarium from Teva Neurosciences, Biogen Idec, Novartis, Genzyme.
No conflicts with this abstract
Dessa Sadovnick:Unrestricted research funds from BioGen Idec, Novartis, Genzyme, Teva NeurosciencesTravel Funds from Roche
No conflicts with this abstract.
Abstract: P863
Type: Poster
Abstract Category: Clinical aspects of MS - MS and gender
Background: Multiple Sclerosis (MS) often affects women at the peak of their reproductive capacity.
Several studies have shown successful reproductive outcomes in women with MS. However, there is a lack of prospective disease-specific, rather then medication-specific, real-world pregnancy registries. There is also a paucity of data related to developmental pediatric outcomes in children born to mothers with MS. Here, we propose a region-specific MS pregnancy study focused on longer-term maternal and pediatric outcomes.
Methods: We developed a data repository that will follow women with MS from any stage of conception to three years post-partum. This prospective cohort investigation will recruit 600 patients from 11 Multiple Sclerosis Clinics and Centers in the New England region of the United States. RedCap database will be used for data processing and storage. The principle site will collect neurologic, obstetric, and pediatric routine care information throughout pregnancy attempts, pregnancy trimesters and for 3 years post partum. Telephone interviews will be conducted every three months during pregnancy and at specified time points post partum. Decoded, de-identified information will be made available for subsequent aggregate analysis.
Results: This unique registry will assess real world practices and outcomes in pregnant MS patients and their children. We expect that maternal outcomes may be influenced by the overall duration off disease-modifying therapy (DMT), lactation choices post-partum, and disease severity pre-partum. We anticipate that pediatric outcomes may be influenced by level of maternal neurologic disability peri-partum, exposure to immune-modulating medications in early pregnancy and socio-economic stressors.
Conclusion: This is the first prospective regional MS pregnancy registry in the United States. Results from this study will contribute to our understanding of maternal and pediatric outcomes in MS and to the development of effective pregnancy and post-partum management programs in this patient population.
Disclosure: Tatenda D Mahlanza: nothing to disclose
Maria Houtchens: Unrestricted research grants from Biogen Idec, GenzymeConsulting honorarium from Teva Neurosciences, Biogen Idec, Novartis, Genzyme.
No conflicts with this abstract
Dessa Sadovnick:Unrestricted research funds from BioGen Idec, Novartis, Genzyme, Teva NeurosciencesTravel Funds from Roche
No conflicts with this abstract.